New Research on the Emotional Impact of Type Finds the Fonts Brands Use Can Impact Consumers' Response, Perception and Trust WOBURN, Mass., May 24, 2022 /PRNewswire/ -- Monotype today released ...
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering ...
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as ...
-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified ...
Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU to earlier use in metastatic breast cancer Based on groundbreaking DESTINY-Breast03 results showing ENHERTU reduced the risk of disease progression or ...
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease ...
ASX: XETRA-DAX: Level 1 ADR:CUV UR9 CLVLY EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five patientsbrain scans (MRI-FLAIR2) in all patients ...
Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemiaStudy ...
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today provides positive results from ...
NORCROSS, Ga., April 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its first data and ...
Copyright © 2015 - 2021 Lifecarenews.in
